TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06285903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: internal sinus lift surgery
Description: surgery approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: internal sinus lift surgery
Description: surgery approach
Study: NCT06016712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish Eye Lenses
Description: Contact lenses used for measuring intraocular pressure.
Study: NCT06305065

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: KUNWU Navigation TKA procedure
Description: In terms of technical specifications, KUNWU is the only robotic arm with seven degrees of freedom, while other systems have a maximum of six. The ergonomic and user-friendly design of the system contributes to physical relief and simplified instrument handling, which enhances surgical precision and reduces cognitive stress.~KUNWU's navigation system boasts a refresh rate of 335Hz, which is significantly higher than the current 60Hz rate of other navigation systems. This high refresh rate provides a clear and visually captivating display of the navigation procedure, eliminating blurriness and indecipherable output. It enables surgeons to react promptly during live procedures, enhancing safety for both clinicians and patients and reducing potential complications and hospitalization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CORI Surgical System TKA procedure
Description: The CORI Surgical System (Smith and Nephew®) represents one of such recent advances in robotics that it can assist surgical planning, and increase the accuracy of implant position due to real-time feedback during the procedure (bone resection, implant position, ligamentous balance).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional TKA procedure
Description: Total knee arthroplasty (TKA) is a highly successful and frequently performed surgical treatment to reduce disability caused by end-stage osteoarthritis and other conditions affecting articular cartilage. Technical outcomes for TKA are excellent, with favorable postoperative health-related quality of life. Also, survivorship of primary knee replacements is excellent with reported survivorship of 82.3% at 25 years. TKA has traditionally been indicated in the elderly population with relatively sedentary lifestyles, but more active, younger patients (\<55) are receiving TKA due to the desire for a pain-free, active lifestyle with the demand projected to continue to increase for this group. A recent systematic review has shown that functional outcomes are similar in this population compared to elderly patients with no increase in the burden of revision.
Study: NCT05695430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy for People with Physical Disabilities
Description: 12 sessions of of Brief Cognitive Behavioral Therapy that has been adapted for people with physical disabilities will be administered through telehelath.
Study: NCT05644509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Virus Injection（Revottack）+PD-1
Description: Intravenous injection of Revottack injection combined with PD-1(Toripalimab） inhibitor
Study: NCT06017466

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Visual Vertigo Analogue Scale (VVAS)
Description: The Visual Vertigo Analogue Scale (VVAS) was developed by E. Dannenbaum et al in 2011 to diagnose visual vertigo. It is a nine-item analogue scale in which the subjects can rated the intensity of their symptoms. The symptoms can be categorized as None (0), Mild (0.1-40), Moderate (40.01-70) or Severe (70.01-100). The VVAS is already available in English and French but a Dutch version does not yet exist.
Study: NCT05255224

Intervention type: OTHER
Intervention: Not applicable as observational study
Description: Not applicable as observational study

Intervention type: OTHER
Intervention: Not applicable as observational study
Description: Not applicable as observational study
Study: NCT05673850

Intervention type: DRUG
Intervention: NET or NCT
Description: In this study, we included 518 ER-positive BC patients who received either neoadjuvant endo-crine therapy (NET) or neoadjuvant chemotherapy (NCT).

Intervention type: DRUG
Intervention: NET or NCT
Description: In this study, we included 518 ER-positive BC patients who received either neoadjuvant endo-crine therapy (NET) or neoadjuvant chemotherapy (NCT).
Study: NCT04650945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isCGM group
Description: As previously described
Study: NCT05367830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Bone@BC app
Description: The bone@BC app is a diary for patients with breast cancer that they can use if they want to.
Study: NCT05823454

Intervention type: DRUG
Intervention: Different drug dosage
Description: Choice of Anesthesia

Intervention type: DRUG
Intervention: Different drug dosage
Description: Choice of Anesthesia

Intervention type: DRUG
Intervention: Different drug dosage
Description: Choice of Anesthesia

Intervention type: DRUG
Intervention: Different drug dosage
Description: Choice of Anesthesia

Intervention type: DRUG
Intervention: Different drug dosage
Description: Choice of Anesthesia
Study: NCT04506424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT Guided Cochlear Implant Programming
Description: Flat Panel (high resolution) CT scans of the temporal bones, including the inner ears, will be obtained. The research team will use the scans to generate custom cochlear implant (CI) programs for use by the participants.
Study: NCT04902885

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trilaciclib, carboplatin, etoposide，or Topotecan
Description: Trilaciclib plus carboplatin, etoposide for first line patients ;Trilaciclib plus Topotecan for second or third line patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trilaciclib, carboplatin, etoposide，or Topotecan
Description: Trilaciclib plus carboplatin, etoposide for first line patients ;Trilaciclib plus Topotecan for second or third line patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo, carboplatin, etoposide，or Topotecan
Description: placebo plus carboplatin, etoposide for first line patients ;placebo plus Topotecan for second or third line patients
Study: NCT06278259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation program bases aerobic and Baduanjin exercises
Description: It is an interventional study in which 60 stroke patients estimated to enrol according to random allocation and divided into two groups. The study group participants involve in Telerehabilitation sessions is based on low-impact rhythmic movements, guided by video, according to the protocol of (Schachter et al., 2003). The telerehabilitation program is moderately intense aerobic exercise 3 times per week and included 3 parts: warm-up, central part, and cool-down. Each session : 30 min, 3 sessions/ week for 3 months.With the Baduanjin exercise program is delivered individually, at each patient's home, through telerehabilitation, with direct remote supervision by a physiotherapist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation program bases aerobic exercises
Description: The telerehabilitation program is moderately intense aerobic exercise 3 times per week and included 3 parts: warm-up, central part, and cool-down. Each session : 30 min, 3 sessions/ week for 3 months.
Study: NCT04701411

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Darvadstrocel
Description: Darvadstrocel perilesional injection.
Study: NCT06023537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss program
Description: All participants will participate in the same remote, behavioral weight loss program. As part of the baseline assessment, participants will be asked to watch a series of custom-made videos on the study's dietary and physical activity prescriptions, dietary self-monitoring, self-weighing, and cognitive-behavioral skills to facilitate engagement in study prescriptions. Participants will be prescribed a reduced-calorie diet that will be individualized based on the individual's starting weight and weight loss goal (recommended goal of 5-10% weight loss over 12 weeks). Participants also will be prescribed a goal of 150 minutes of moderate-to-vigorous physical activity per week. They are also given, free of cost, a Fitbit Charge 5 health tracker, the Fitbit Aria Air digital scale, and a MyFitnessPal Premium subscription for the duration of the study.
Study: NCT05651191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human CD19 Targeted DASH CAR-T Cells Injection
Description: Autologous genetically modified anti-CD19 CAR transduced T cells
Study: NCT04360694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incremental hemodialysis
Description: 95 patients will start renal replacement therapy (RRT) with an incremental hemodialysis (once-weekly or twice-weekly) regimen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hemodialysis
Description: 95 patients will start renal replacement therapy (RRT) with the standard (thrice-weekly) hemodialysis regimen.
Study: NCT05580692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Biospecimen Sample Collection
Study: NCT06547541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A body weight based resistance training.
Study: NCT06561646

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-port robotic-assisted nipple-sparing mastectomy and sentinel lymph node biopsy
Description: the single-port robotic-assisted nipple-sparing mastectomy and sentinel lymph node biopsy in the management of breast cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-port robotic-assisted nipple-sparing mastectomy and axillary lymph node dissection
Description: the single-port robotic-assisted nipple-sparing mastectomy and axillary lymph node dissection in the management of breast cancer
Study: NCT04300946

Intervention type: DEVICE
Intervention: TMS targeted on the cerebellum
Description: Impact on EEG performance (preparation wave in temporal tasks) of cerebellar stimulation by MSD in healthy subjects. The contrast between the post-stimulation effects of verrum stimulation and placebo stimulation will indicate the magnitude of the effect and will allow us to optimize the type of protocol that may be useful in schizophrenia.

Intervention type: DEVICE
Intervention: TMS targeted on the cerebellum
Description: Impact on EEG performance (preparation wave in temporal tasks) of cerebellar stimulation by MSD in healthy subjects. The contrast between the post-stimulation effects of verrum stimulation and placebo stimulation will indicate the magnitude of the effect and will allow us to optimize the type of protocol that may be useful in schizophrenia.

Intervention type: DEVICE
Intervention: TMS targeted on the cerebellum
Description: Impact on EEG performance (preparation wave in temporal tasks) of cerebellar stimulation by MSD in healthy subjects. The contrast between the post-stimulation effects of verrum stimulation and placebo stimulation will indicate the magnitude of the effect and will allow us to optimize the type of protocol that may be useful in schizophrenia.

Intervention type: DEVICE
Intervention: TMS targeted on the cerebellum
Description: Impact on EEG performance (preparation wave in temporal tasks) of cerebellar stimulation by MSD in healthy subjects. The contrast between the post-stimulation effects of verrum stimulation and placebo stimulation will indicate the magnitude of the effect and will allow us to optimize the type of protocol that may be useful in schizophrenia.
Study: NCT04820309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline and Trospium Chloride Capsules
Description: Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
Study: NCT06478953

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FA Pneumonia Panel
Description: A single BioFire® FilmArray® Pneumonia Panel assay will be performed on a respiratory clinical specimen.
Study: NCT06547164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camizestrant
Description: Camizestrant will be administered orally.
Study: NCT04648371

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation and Transcranial Direct Current Stimulation
Description: Cognitive Remediation (CR) is a well-established psychosocial group intervention that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.~Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation method that can be safely administered to awake outpatients. It does not require general anesthesia or surgical implantation. It utilizes low intensity electrical current (e.g., 2 mA) either to increase cortical excitability with an anodal electrode or to suppress cortical excitability with a cathodal electrode.
Study: NCT05747807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous intradiscal radiofrequency treatment
Description: using heat created by radiofrequency electrode to destroy the nociceptive pain fibres and enhance the structural integrity of the disc
Study: NCT04648371

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cognitive Remediation and Transcranial Direct Current Stimulation
Description: Cognitive Remediation (CR) is a well-established psychosocial group intervention that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.~Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation method that can be safely administered to awake outpatients. It does not require general anesthesia or surgical implantation. It utilizes low intensity electrical current (e.g., 2 mA) either to increase cortical excitability with an anodal electrode or to suppress cortical excitability with a cathodal electrode.
Study: NCT05126485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haptic Biofeedback from SageMotion Biofeedback System
Description: Haptic biofeedback units (vibrating motors) will be placed on individual body segments. The haptic biofeedback system will be configured to provide vibratory stimuli when a target minimum hip extension angle is reached during the loading response. The minimum threshold will be determined by the therapist based on the patient's current ability. Specifically, the system will target a 10-20% increase in extension angle from their current level, as identified by the therapist. A vibration stimulus will be first applied each time this minimum angle is achieved, and will continually increase in intensity in proportion to the degree with which the patient exceeds this minimum value. The stimuli will stop being applied when the extension angle drops back below the threshold. These intensity-modulated stimuli have been selected to encourage the patient to exceed the minimum threshold rather than stop extending when the stimulus is first applied
Study: NCT05215483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customised testing advice
Description: Customised advice: With Corona related symptoms, get tested at a test facility. If this isn't possible, use a Lateral Flow test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customised testing advice
Description: Customised advice: With Corona related symptoms, get tested at a test facility. If this isn't possible, use a Lateral Flow test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular testing advice
Description: Government guideline testing advice: With Corona related symptoms, get tested at a test facility.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular testing advice
Description: Government guideline testing advice: With Corona related symptoms, get tested at a test facility.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LFT available
Description: LFT availability: Enough lateral flow tests available at home

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LFT available
Description: LFT availability: Enough lateral flow tests available at home

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No LFT available
Description: LFT availability: No lateral flow tests available at home

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No LFT available
Description: LFT availability: No lateral flow tests available at home
Study: NCT05400694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Dairy products with reduced sugar content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Dairy products with reduced sugar content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Dairy products with reduced sugar content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Dairy products with reduced sugar content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Dairy products with reduced sugar content
Study: NCT06547164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camizestrant
Description: Camizestrant will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Carbamazepine will be administered orally.
Study: NCT06553885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Enfortumab vedotin is a type of prescription medicine known as an antibody-drug conjugate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Enfortumab vedotin is a type of prescription medicine known as an antibody-drug conjugate.
Study: NCT06109181

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LX2020
Description: LX2020 is an adeno-associated viral vector encoding the human Plakophilin-2 (PKP2) gene (AAVrh.10hPKP2)
Study: NCT06165965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: SGLT2 dual inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: SGLT2 dual inhibitor
Study: NCT05730673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700mg leronlimab weekly dose
Description: leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80mg Regorafenib at week 1
Description: Regorafenib is a small-molecule multiple kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120mg Regorafenib at week2
Description: Regorafenib is a small-molecule multiple kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 160 mg Regorafenib at week 3
Description: Regorafenib is a small-molecule multiple kinase inhibitor
Study: NCT06208631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait retraining
Description: Changing muscle coordination while walking
Study: NCT06173648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser and ICG solution.
Description: Intervention consists of addition of a combined laser absorption solution and infrared diode laser. The solution is introduced into the prepared pulp chamber and root canals, allowed to dwell for 1 minute, followed by exposure to the laser energy delivered via a fiber optic introduced into the root canal, and while activating the laser at 2.5 watts of optical output with a pulse duration of 100 msec and a pulse gap of 300 msec, the solution and residual structures in the root and pulp chamber are exposure over the course of 30 seconds, moving and relocating the fiber tip throughout the canals and chamber during that time. The laser is halted and a wait time of 30 seconds is applied. The laser fiber is then reintroduced and another 30 second exposure, repeating the same settings and technique.
Study: NCT05388305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR--γδT cells
Description: Biological: CAR-γδT; Drug:
Study: NCT06241963

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Unilateral real High definition transcranial direct current stimulation
Description: Improvement of cortical excitability, unilateral stimulation was effective, and no side effects were observed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Bilateral real High definition transcranial direct current stimulation
Description: Improved cortical excitability, the effect was more obvious than unilateral stimulation, the effect lasted longer, and no side effects were observed

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Sham High definition transcranial direct current stimulation
Description: The sham stimulation is mainly used for blank control, control variables, and exclude the interference of other factors
Study: NCT06035250

Intervention type: DRUG
Intervention: Neoadjuvant Chemotherapy
Description: Participants in this group are diagnosed with gastric cancer and are scheduled to undergo neoadjuvant chemotherapy as a part of their treatment regimen. The specific chemotherapy drugs, dosages, and schedules will be determined according to established clinical guidelines and the participant's specific condition.